USO 25087
GO46021 - A PHASE Ib/PHASE II MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-4198 ALONE AND IN COMBINATION WITH GIREDESTRANT IN COMPARISON WITH ABEMACICLIB AND GIREDESTRANT IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC ESTROGEN RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER WHO HAVE PREVIOUSLY PROGRESSED DURING OR AFTER A CDK4/6 INHIBITOR
Disease Types: Breast Cancer Research
Eligibility Requirements:
• ER+ (≥ 1%), HER-negative (local testing) LA or MBC
• PD on/after tx with CDK4/6 inhibitor and ET in the LA/MBC
setting
• More than 1 line of tx for LA/MBC are excluded
• Prior chemotherapy for MBC excluded
• Tx with approved oral ET within 7 days prior to initiation of study
drug or tx with fulvestrant/approved CDK4/6 inhibitor within 21
days prior to initiation of study drug are excluded
• Measurable/non-measurable evaluable (including bone only)
disease per RECIST v1.1
• Most recent collected and representative tumor tissue must be
provided
• Known and untreated or active CNS metastases are excluded
For more information on this trial CLICK HERE.
Available at: